ClinVar Miner

Submissions for variant NM_000297.4(PKD2):c.290AGG[7] (p.Glu102dup) (rs750077647)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000173103 SCV000224188 likely benign not specified 2014-07-15 criteria provided, single submitter clinical testing
Invitae RCV000200241 SCV000255284 benign Autosomal dominant polycystic kidney disease 2019-12-31 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV000173103 SCV000614572 benign not specified 2017-04-26 criteria provided, single submitter clinical testing
Mendelics RCV000987456 SCV001136751 benign Polycystic kidney disease 2 2019-05-28 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001356905 SCV001552191 likely benign not provided no assertion criteria provided clinical testing The PKD2 p.Glu102dup variant was identified in 2 of 1564 proband chromosomes (frequency: 0.001) from French, British, and North America individuals or families with ADPKD (Audrezet 2012, Garcia-Gonzalez 2007). There is conflicting evidence in the literature and databases. The variant was identified in a 54 year old male patient with bilateral multicystic kidneys and situs inverus, the duplication segregating with the disease (cystic kidneys) in 1 of the proband’s children and was absent in the 3 unaffected children suggesting that the variant is disease causing (Bataille 2011). The variant was identified in dbSNP (ID: rs547253972) as “NA”, Clinvitae database (classification likely benign and benign), the ClinVar database (classification benign by Invitae and likely benign by Emory Genetics), the ADPKD Mutation Database (classification indeterminate), and COSMIC (1X in a lung carcinoma). This variant was also identified in the 1000 Genomes Project in 37 of 5000 chromosomes (frequency: 0.0074), HAPMAP-AFR in 32 of 1322 chromosomes (frequency: 0.0242), HAPMAP-AMR in 3 of 694 chromosomes (frequency: 0.0043), HAPMAP-EUR in 2 of 1006 chromosomes (frequency: 0.002), and in the Exome Aggregation Consortium database (August 8th 2016) in 928 of 11372 chromosomes (freq. 0.0816) in the following populations: South Asian in 662 of 7216 chromosomes (freq. 0.09), European (Non-Finnish) in 229 of 3242 chromosomes (freq. 0.07), Other in 8 of 128 chromosomes (freq. 0.06), Latino in 8 of 164 chromosomes (freq. 0.05), African in 16 of 442 chromosomes (freq. 0.04), East Asian in 5 of 172 chromosomes (freq. 0.02) but was not seen in the Finnish populations. This high frequency of observations in a control database strongly suggests that the variant is not clinically significant. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. This variant is an in-frame duplication resulting in the addition of a Glutamic acid residue at codon 102; the impact of this alteration on PKD2 protein function is not known. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.